First treatment option indicated for CKD in Scotland for 20 years
NICE recommendation for Forxiga could entitle 53,000 adults to the new kidney disease therapy
Read More
Tag: CKD
AZ’ Farxiga hits all goals in chronic kidney disease trial
The drug significantly reduced the worsening of renal function or risk of death in patients with chronic kidney disease with and without type II diabetes
Read More
Bayer’s finerenone hits targets in diabetes/kidney disease trial
The drug hit primary and secondary goals of the Phase III FIDELIO-DKD renal outcomes study
Read More
New COVID-10 guidelines for CKD and interstitial lung disease
The guidelines should help healthcare professionals decide what care to provide for people without COVID-19 infection or with confirmed or suspected infection safely while making the best use of NHS resources
Read More
Astellas’ kidney disease drug shows promise in PhIII
A Phase III study assessing Astellas’ roxadustat in patients with chronic kidney disease (CKD) and anaemia who are not receiving dialysis has met its key endpoints.
Read More
UK study to investigate kidney disease progression
A large-scale observational study of chronic kidney disease (CKD) is due to launch in general practices this month, involving 3,205 Oxfordshire residents and led by Oxford University researchers.
Read More
US nod for Amgen’s Parsabiv
Amgen’s Parsabiv has now been cleared for use in the US to treat secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis, after it was initially rejected by the US Food and Drug Administration in October last year.
Read More
GSK kicks off Phase III programme for daprodustat
GlaxoSmithKline has begun Phase III development of daprodustat, testing its potential as a treatment for anaemia associated with chronic kidney disease (CKD).
Read More
- MRM Health collaborates with Oncode Institute and Netherlands Cancer Institute
- Sobi to acquire Arthrosi Therapeutics, strengthening gout treatment pipeline
- Lindus Health and Quotient Sciences announce strategic partnership to accelerate drug development
- Title21 Health Solutions joins the Blood and Cells Advocacy Roster
- NADMED launches $30,000 metabolomics research award
